Adaptimmune Therapeutics (NASDAQ:ADAP) Posts Earnings Results

Adaptimmune Therapeutics (NASDAQ:ADAP) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), Zacks reports. The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.25 on Wednesday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm has a market cap of $63.97 million, a PE ratio of -1.14 and a beta of 2.52. The business has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $0.68. Adaptimmune Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.65.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wells Fargo & Company dropped their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. Mizuho dropped their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Scotiabank decreased their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. Finally, StockNews.com began coverage on shares of Adaptimmune Therapeutics in a research report on Friday, March 21st. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $2.18.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.